Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …

Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Background There is an unmet need for a treatment for psoriasis that results in complete
skin clearance with a reliably quick response. Bimekizumab is a monoclonal IgG1 antibody …

Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Background Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with
psoriasis have been reported. Objectives To assess the prevalence and incidence of PsA in …

Psoriasis is caused by a complex interplay between the immune system, psoriasis-
associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both
interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared …

The T helper 17 (Th17) cell pathway has been linked by genome-wide association studies to
multiple autoimmune diseases. Identification of the genetic causes of primary …